Advanced glycation end products promote hepatosteatosis by interfering with SCAP-SREBP pathway in fructose-drinking mice

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 305, Issue 6, 2013, Pages

  Mastrocola, Raffaella ^a   Collino, Massimo ^a   Rogazzo, Mara ^a   Medana, Claudio ^a   Nigro, Debora ^a   Boccuzzi, Giuseppe ^b   Aragno, Manuela ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

AGEs; Carboxymethyl lysine; Fructose; Glucose; Hepatosteatosis; Soft drink; SREBP; Triglyceride synthesis

Indexed keywords

ADVANCED GLYCATION END PRODUCT; FRUCTOSE; LYSINE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; FATTY LIVER; IMMUNOFLUORESCENCE; IMMUNOPRECIPITATION; LIPOGENESIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUGAR INTAKE;

AGES; CARBOXYMETHYL LYSINE; FRUCTOSE; GLUCOSE; HEPATOSTEATOSIS; SOFT DRINK; SREBP; TRIGLYCERIDE SYNTHESIS;

ANIMALS; DRINKING; FATTY LIVER; FRUCTOSE; GLUCOSE; GLUCOSE INTOLERANCE; GLYCOSYLATION END PRODUCTS, ADVANCED; HYPOGLYCEMIA; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LIPIDS; LIVER; LYSINE; MALE; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; SIGNAL TRANSDUCTION; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TRIGLYCERIDES;

EID: 84884410878     PISSN: 01931857     EISSN: 15221547     Source Type: Journal    
DOI: 10.1152/ajpgi.00450.2012     Document Type: Article

References (52)

1. Ahmed N, Furth AJ. Failure of common glycation assays to detect glycation by fructose. Clin Chem 38: 1301-1303, 1992.
2. Alderson NL, Chachich ME, Youssef NN, Beattie RJ, Nachtigal M, Thorpe SR, Baynes JW. The AGE inhibitor pyridoxamine inhibits lipemia and development of renal and vascular disease in Zucker obese rats. Kidney Int 63: 2123-2133, 2003.
3. Aragno M, Mastrocola R, Medana C, Restivo F, Catalano MG, Pons N, Danni O, Boccuzzi G. Up-regulation of advanced glycated products receptors in the brain of diabetic rats is prevented by antioxidant treatment. Endocrinology 146: 5561-5567, 2005.
4. Bierhaus A, Humpert PM, Morcos M, Wendt T, Chavakis T, Arnold B, Stern DM, Nawroth PP. Understanding RAGE, the receptor for advanced glycation end products. J Mol Med 83: 876-86, 2005.
5. Bohlender JM, Franke S, Stein G, Wolf G. Advanced glycation end products and the kidney. Am J Physiol Renal Physiol 289: F645-F659, 2005.
6. Bray GA. Soft drink consumption and obesity: it is all about fructose. Curr Opin Lipidol 21: 51-57, 2010.
7. Brown MS, Goldstein JL. Selective versus total insulin resistance. Cell Metab 7: 95-96, 2008.
8. Choi SH, Ginsberg HN. Increased very low density lipoprotein (VLDL) secretion, hepatic steatosis, and insulin resistance. Trends Endocrinol Metab 22: 353-363, 2011.
9. Elliott SS, Keim NL, Stern JS, Teff K, Havel PJ. Fructose, weight gain, and the insulin resistance syndrome. Am J Clin Nutr 76: 911-922, 2002.
10. Espenshade PJ, Hughes AL. Regulation of sterol synthesis in eukaryotes. Annu Rev Genet 41: 401-427, 2007.
11. Ferré P, Foufelle F. Hepatic steatosis: a role for de novo lipogenesis and the transcription factor SREBP-1c. Diabetes Obes Metab 2: 83-92, 2010.
12. Gaens KH, Niessen PM, Rensen SS, Buurman WA, Greve JW, Driessen A, Wolfs MG, Hofker MH, Bloemen JG, Dejong CH, Stehou-wer CD, Schalkwijk CG. Endogenous formation of N-(carboxymethyl) lysine is increased in fatty livers and induces inflammatory markers in an in vitro model of hepatic steatosis. J Hepatol 56: 647-655, 2012.
13. Galler A, Müller G, Schinzel R, Kratzsch J, Kiess W, Münch G. Impact of metabolic control and serum lipids on the concentration of advanced glycation end products in the serum of children and adolescents with type 1 diabetes, as determined by fluorescence spectroscopy and N-(carboxymethyl)lysine ELISA. Diabetes Care 26: 2609-2615, 2003.
14. Germanová A, Koucký M, Hájek Z, Parízek A, Zima T, Kalousová M. Soluble receptor for advanced glycation end products in physiological and pathological pregnancy. Clin Biochem 43: 442-446, 2010.
15. Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res 107: 1058-1070, 2010.
16. Goldin A, Beckman JA, Schmidt AM, Creager MA. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 114: 597-605, 2006.
17. Goldstein JL, Bose-Boyd RA, Brown MS. Protein sensors for membrane sterols. Cell 124: 35-46, 2006.
18. Hellerstein MK, Schwarz JM, Neese RA. Regulation of hepatic de novo lipogenesis in humans. Annu Rev Nutr 16: 523-557, 1996.
19. Hofmann SM, Tschop MH. Dietary sugars: a fat difference. J Clin Invest 119: 1089-1092, 2009.
20. Kanner J. Dietary advanced lipid oxidation endproducts are risk factors to human health. Mol Nutr Food Res 51: 1094-1101, 2007.
21. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, Yeh M, McCullough AJ, Sanyal AJ; Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41: 1313-1321, 2005.
22. Koo HY, Miyashita M, Cho BH, Nakamura MT. Replacing dietary glucose with fructose increases ChREBP activity and SREBP-1 protein in rat liver nucleus. Biochem Biophys Res Commun 390: 285-289, 2009.
23. Lanaspa MA, Sanchez-Lozada LG, Choi YJ, Cicerchi C, Kanbay M, Roncal-Jimenez CA, Ishimoto T, Li N, Marek G, Duranay M, Schreiner G, Rodriguez-Iturbe B, Nakagawa T, Kang DH, Sautin YY, Johnson RJ. Uric acid induces hepatic steatosis by generation of mitochondrial oxidative stress: potential role in fructose-dependent and-independent fatty liver. J Biol Chem 287: 40732-40744, 2012.
24. Lanaspa MA, Sanchez-Lozada LG, Cicerchi C, Li N, Roncal-Jimenez CA, Ishimoto T, Le M, Garcia GE, Thomas JB, Rivard CJ, Andres-Hernando A, Hunter B, Schreiner G, Rodriguez-Iturbe B, Sautin YY, Johnson RJ. Uric acid stimulates fructokinase and accelerates fructose metabolism in the development of fatty liver. PLoS One 7: e47948, 2012.
25. Lim JS, Mietus-Snyder M, Valente A, Schwarz JM, Lustig RH. The role of fructose in the pathogenesis of NAFLD and the metabolic syndrome. Nat Rev Gastroenterol Hepatol 7: 251-264, 2010.
26. Madero M, Perez-Pozo SE, Jalal D, Johnson RJ, Sanchez-Lozada LG. Dietary fructose and hypertension. Curr Hypertens Rep 13: 29-35, 2011.
27. Makita Z, Vlassara H, Cerami A, Bucala R. Immunochemical detection of advanced glycosylation end products in vivo. J Biol Chem 267: 5133-5138, 1992.
28. Mastrocola R, Guglielmotto M, Medana C, Catalano MG, Cutrupi S, Borghi R, Tamagno E, Boccuzzi G, Aragno M. Dysregulation of SREBP2 induces BACE1 expression. Neurobiol Dis 44: 116-124, 2011.
29. Mori T, Kondo H, Hase T, Murase T. Dietary phospholipids ameliorate fructose-induced hepatic lipid and metabolic abnormalities in rats. J Nutr 141: 2003-2009, 2011.
30. Ngo Sock ET, Lê KA, Ith M, Kreis R, Boesch C, Tappy L. Effects of a short-term overfeeding with fructose or glucose in healthy young males. Br J Nutr 103: 939-943, 2010.
31. Nohturfft A, Bose-Boyd RA, Scheek S, Goldstein JL, Brown MS. Sterols regulate cycling of SREBP cleavage-activating protein (SCAP) between endoplasmic reticulum and Golgi. Proc Natl Acad Sci USA 96: 11235-11240, 1999.
32. Nomura K, Yamanouchi T. The role of fructose-enriched diets in mechanisms of nonalcoholic fatty liver disease. J Nutr Biochem 23: 203-208, 2012.
33. Nseir W, Nassar F, Assy N. Soft drinks consumption and nonalcoholic fatty liver disease. World J Gastroenterol 16: 2579-2588, 2010.
34. Odetti P, Cosso L, Pronzato MA, Dapino D, Gurreri G. Plasma advanced glycosylation end-products in maintenance haemodialysis patients. Nephrol Dial Transplant 10: 2110-2113, 1995.
35. Ouyang X, Cirillo P, Sautin Y, McCall S, Bruchette JL, Diehl AM, Johnson RJ, Abdelmalek MF. Fructose consumption as a risk factor for non-alcoholic fatty liver disease. J Hepatol 48: 993-999, 2008.
36. Ruiz-Ramírez A, Chávez-Salgado M, Peñeda-Flores JA, Zapata E, Masso F, El-Hafidi M. High-sucrose diet increases ROS generation, FFA accumulation, UCP2 level, and proton leak in liver mitochondria. Am J Physiol Endocrinol Metab 301: E1198-E1207, 2011.
37. Sato R. Sterol metabolism and SREBP activation. Arch Biochem Biophys 501: 177-181, 2010.
38. Schalkwijk CG, Stehouwer CD, van Hinsbergh VW. Fructose-mediated non-enzymatic glycation: sweet coupling or bad modification. Diabetes Metab Res Rev 20: 369-382, 2004.
39. Shangari N, Poon R, O'Brien PJ. Hepatocyte methylglyoxal (MG) resistance is overcome by inhibiting aldo-keto reductases and glyoxalase I catalysed MG metabolism. In: Enzymology and Molecular Biology of Carbonyl Metabolism, edited by Weiner H, Plapp B, Lindahl R, Maser E. West Lafayette, IN: Purdue Univ. Press, vol. 12, p. 266-275, 2005.
40. Silbernagel G, Machann J, Unmuth S, Schick F, Stefan N, Häring HU, Fritsche A. Effects of 4-week very-high-fructose/glucose diets on insulin sensitivity, visceral fat and intrahepatic lipids: an exploratory trial. Br J Nutr 106: 79-86, 2011.
41. Singh R, Barden A, Mori T, Beilin L. Advanced glycation end-products: a review. Diabetologia 44: 129-146, 2001.
42. Stanhope KL, Schwarz JM, Keim NL, Griffen SC, Bremer AA, Graham JL, Hatcher B, Cox CL, Dyachenko A, Zhang W, McGahan JP, Seibert A, Krauss RM, Chiu S, Schaefer EJ, Ai M, Otokozawa S, Nakajima K, Nakano T, Beysen C, Hellerstein MK, Berglund L, Havel PJ. Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans. J Clin Invest 119: 1322-1334, 2009.
43. Suarez G, Rajaram R, Oronsky AL, Gawinowicz MA. Nonenzymatic glycation of bovine serum albumin by fructose (fructation). Comparison with the Maillard reaction initiated by glucose. J Biol Chem 264: 3674-3679, 1989.
44. Takeuchi M, Iwaki M, Takino J, Shirai H, Kawakami M, Bucala R, Yamagishi S. Immunological detection of fructose-derived advanced glycation end-products. Lab Invest 90: 1117-1127, 2010.
45. Tappy L, Lê KA. Metabolic effects of fructose and the worldwide increase in obesity. Physiol Rev 90: 23-46, 2010.
46. Tappy L, Lê KA. Does fructose consumption contribute to non-alcoholic fatty liver disease? Clin Res Hepatol Gastroenterol 36: 554-560, 2012.
47. Targher G. Non-alcoholic fatty liver disease, the metabolic syndrome and the risk of cardiovascular disease: the plot thickens. Diabetologia 51: 444-450, 2008.
48. Teff KL, Grudziak J, Townsend RR, Dunn TN, Grant RW, Adams SH, Keim NL, Cummings BP, Stanhope KL, Havel PJ. Endocrine and metabolic effects of consuming fructose-and glucose-sweetened beverages with meals in obese men and women: influence of insulin resistance on plasma triglyceride responses. J Clin Endocrinol Metab 94: 1562-1569, 2009.
49. Thornalley PJ, Battah S, Ahmed N, Karachalias N, Agalou S, Babaei-Jadidi R, Dawnay A. Quantitative screening of advanced glycation endproducts in cellular and extracellular proteins by tandem mass spectrometry. Biochem J 375: 581-592, 2003.
50. Thuy S, Ladurner R, Volynets V, Wagner S, Strahl S, Königsrainer A, Maier KP, Bischoff SC, Bergheim I. Nonalcoholic fatty liver disease in humans is associated with increased plasma endotoxin and plasminogen activator inhibitor 1 concentrations and with fructose intake. J Nutr 138: 1452-1455, 2008.
51. Velasco A, Hendricks L, Moremen KW, Tulsiani DR, Touster O, Farquhar MG. Cell type-dependent variations in the subcellular distribution of alpha-mannosidase I and II. J Cell Biol 122: 39-51, 1993.
52. Yuan Y, Zhao L, Chen Y, Moorhead JF, Varghese Z, Powis SH, Minogue S, Sun Z, Ruan XZ. Advanced glycation end products (AGEs) increase human mesangial foam cell formation by increasing Golgi SCAP glycosylation in vitro. Am J Physiol Renal Physiol 301: F236-F243, 2011.